Partnerships Involved in Public Health Testing for Zika Virus in Florida, 2016.


Journal

Public health reports (Washington, D.C. : 1974)
ISSN: 1468-2877
Titre abrégé: Public Health Rep
Pays: United States
ID NLM: 9716844

Informations de publication

Date de publication:
Historique:
entrez: 5 11 2019
pubmed: 5 11 2019
medline: 20 2 2020
Statut: ppublish

Résumé

The emergence of Zika virus in the Americas in 2015 and its association with birth defects and other adverse health outcomes triggered an unprecedented public health response and a demand for testing. In 2016, when Florida exceeded state public health laboratory capacity for diagnostic testing, the state formed partnerships with federal and commercial laboratories. Eighty-two percent of the testing (n = 33 802 of 41 008 specimens) by the laboratory partners, including Florida's Bureau of Public Health Laboratories (BPHL; n = 13 074), a commercial laboratory (n = 19 214), and the Centers for Disease Control and Prevention (CDC; n = 1514), occurred from July through November 2016, encompassing the peak period of local transmission. These partnerships allowed BPHL to maintain acceptable test turnaround times of 1 to 4 days for nucleic acid testing and 3 to 7 days for serologic testing. Lessons learned from this response to inform future outbreaks included the need for early planning to establish outside partnerships, adding specimen triage strategies to surge plans, and integrating state and CDC information systems.

Identifiants

pubmed: 31682557
doi: 10.1177/0033354919867720
pmc: PMC6832035
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

43S-52S

Références

Emerg Infect Dis. 2008 Aug;14(8):1232-9
pubmed: 18680646
N Engl J Med. 2016 Apr 21;374(16):1552-63
pubmed: 27028561
Obstet Gynecol. 2016 Oct;128(4):724-30
pubmed: 27479770

Auteurs

Lea Heberlein-Larson (L)

Florida Department of Health, Bureau of Public Health Laboratories, Tampa, FL, USA.

Leah D Gillis (LD)

Florida Department of Health, Bureau of Public Health Laboratories, Miami, FL, USA.

Andrea Morrison (A)

Florida Department of Health, Bureau of Epidemiology, Tallahassee, FL, USA.

Blake Scott (B)

Florida Department of Health, Bureau of Epidemiology, Tallahassee, FL, USA.

Mary Cook (M)

Florida Department of Health, Bureau of Public Health Laboratories, Miami, FL, USA.

Andrew Cannons (A)

Florida Department of Health, Bureau of Public Health Laboratories, Tampa, FL, USA.

Elesi Quaye (E)

Florida Department of Health, Bureau of Public Health Laboratories, Miami, FL, USA.

Stephen White (S)

Florida Department of Health, Bureau of Public Health Laboratories, Miami, FL, USA.

Marshall Cone (M)

Florida Department of Health, Bureau of Public Health Laboratories, Tampa, FL, USA.

Valerie Mock (V)

Florida Department of Health, Bureau of Public Health Laboratories, Jacksonville, FL, USA.

Jarad Schiffer (J)

Division of Bacterial Diseases, Meningitis and Vaccine Preventable Disease Branch, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

David Lonsway (D)

Division of Health Care Quality Promotion, Clinical and Environmental Microbiology Branch, National Center for Emerging Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Marla Petway (M)

National Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Aaron Otis (A)

Division of State and Local Readiness, Program Services Branch, Center for Preparedness and Response, Centers for Disease Control and Prevention, Tallahassee, FL, USA.

Danielle Stanek (D)

Florida Department of Health, Bureau of Epidemiology, Tallahassee, FL, USA.

Janet Hamilton (J)

Florida Department of Health, Bureau of Epidemiology, Tallahassee, FL, USA.

Susanne Crowe (S)

Florida Department of Health, Bureau of Public Health Laboratories, Jacksonville, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH